Four-Drug attack on stomach cancer aims to make inoperable tumors removable
NCT ID NCT07353684
Summary
This study is testing a combination of four drugs to shrink advanced stomach or gastroesophageal junction cancer tumors, with the goal of making them operable for surgical removal. It will enroll about 49 adults who have not had prior cancer treatment and whose cancer is currently considered inoperable. The main goals are to see if the treatment can successfully shrink tumors enough for surgery and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADEBRELIMAB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.